This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety Study of Radiofrequency Ablation of Locally Advanced Pancreatic Cancer (RFA of LAPC)

This study has been completed.
Information provided by (Responsible Party):
R. van Hillegersberg, UMC Utrecht Identifier:
First received: June 20, 2012
Last updated: January 29, 2015
Last verified: January 2015
The purpose of the study is to determine the safety of radiofrequency ablation of locally advanced pancreatic cancer that can not be surgically removed with the current standard procedures. Complications after the operation will be registered. Moreover a pain score will be determined, length of hospital stay, chemotherapy, survival, progression free survival and a tumour marker.

Condition Intervention Phase
Locally Advanced Pancreatic Cancer Procedure: radiofrequency ablation (RFA) Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study: Radiofrequency Ablation of Locally Advanced Pancreatic Cancer

Resource links provided by NLM:

Further study details as provided by R. van Hillegersberg, UMC Utrecht:

Primary Outcome Measures:
  • Safety [ Time Frame: Within 30 days after the RFA procedure ]
    The safety will be specified as the percentage of patients with complications directly related to RFA and the routinely performed double-bypass procedure, requiring re-intervention (i.e. endoscopy, radiology, or surgery). This is also known as a complication of grade III or higher in the Clavien-Dindo classification (internationally accepted classification for surgical complications). Moreover all in-hospital complications or complications developed within 30 days after the RFA procedure will be evaluated according to the Clavien-Dindo classification.

Secondary Outcome Measures:
  • survival [ Time Frame: 2 years after RFA procedure ]
  • VAS pain score [ Time Frame: 3 months ]
  • length hospital stay [ Time Frame: 3 months ]
  • progression free survival [ Time Frame: 2 years after RFA procedure ]
  • CA19-9 response [ Time Frame: 2 years after RFA procedure ]
  • Chemotherapy [ Time Frame: 2 years ]
    Type, frequency, dosage and duration of chemotherapy will be registered.

Enrollment: 17
Study Start Date: September 2012
Study Completion Date: November 2014
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: radiofrequency ablation Procedure: radiofrequency ablation (RFA)
RFA with CELON bipolar probes. Settings: Power 30 watts, total energy 15 KJ.
Other Name: CELON Power System, CE mark 0197

Detailed Description:
Pancreatic cancer is the fourth leading cause of cancer related death in the Western world. At time of diagnosis, 20% of patients present with a resectable tumour, 40% with an irresectable locally advanced tumour (without metastases) and 40% with metastatic disease. The median survival of patients with irresectable locally advanced pancreatic cancer is only 6 months. Currently, there is no effective treatment for these patients. Therefore, there is an urgent need for new therapies. Radiofrequency ablation (RFA) is a technique that has been demonstrated to be effective in the treatment of several irresectable tumours. RFA produces local tumour destruction through high frequency alternating current flowing from an electrode implanted directly into the tumour and causing frictional heating. The purpose of this study is to determine the safety of RFA-pancreas in patients with non-metastasized, irresectable, locally advanced pancreatic cancer.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with irresectable locally advanced pancreatic cancer found at laparotomy with histologic diagnosis before start of RFA
  2. Patient considered eligible to undergo pancreatic surgery as assessed by the general criteria of the departments of anaesthesiology and surgery of the UMC Utrecht
  3. Fully informed written consent given

Exclusion Criteria:

  1. Patients younger than 18 years
  2. Pregnancy
  3. Patients with distant metastases
  4. Portal vein thrombosis seen on CT preoperatively
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01628458

University Medical Center Utrecht
Utrecht, Netherlands, 3584 CX
Sponsors and Collaborators
UMC Utrecht
Principal Investigator: Richard van Hillegersberg, Professor UMC Utrecht
  More Information

Responsible Party: R. van Hillegersberg, Professor in surgery, UMC Utrecht Identifier: NCT01628458     History of Changes
Other Study ID Numbers: 12-018
Study First Received: June 20, 2012
Last Updated: January 29, 2015

Keywords provided by R. van Hillegersberg, UMC Utrecht:
Pancreatic cancer
locally advanced

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases processed this record on September 21, 2017